Sushant Mohan Ranadive

Sushant Mohan Ranadive

Auto-generated profile, based on publicly available information

Sushant Mohan Ranadive

Department of Kinesiology, College Park School of Public Health University of Maryland College Park Maryland USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Circulation
Verified
Journal Article
Closed access
BZBin Zhang
Bin Zhang
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
HSHartzell Vernon Schaff
Hartzell Vernon Schaff
HMHector I. Michelena
Hector I. Michelena
CRCarolyn M. Roos
Carolyn M. Roos
JMJordan D. Miller
Jordan D. Miller
BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS. METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis. RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02481258). CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02481258.

22 February 2022 in IEEE Journal of Selected Topics in Signal Processing
Verified
Journal Article
Closed access
XTXin Tian
Xin Tian
CWChau-Wai Wong
Chau-Wai Wong
SRSushant M. Ranadive
Sushant M. Ranadive
MWMin Wu
Min Wu
Blood oxygen saturation (SpO $_2$ ) is an important indicator forpulmonary and respiratory functionalities. Clinical findings on COVID-19 show that many patients had dangerously low blood oxygen levels not long before conditions worsened. It is therefore recommended, especially for the vulnerable population, to regularly monitor the blood oxygen level for precaution. Recent works have investigated how ubiquitous smartphone cameras can be used to infer SpO $_2$ . Most of these works are contact-based, requiring users to cover a phone’s camera and its nearby light source with a finger to capture reemitted light from the illuminated tissue. Contact-based methods may lead to skin irritation and sanitary concerns, especially during a pandemic. In this paper, we propose a noncontact method for SpO $_2$ monitoring using hand videos acquired by smartphones. Considering the optical broadband nature of the red (R), green (G), and blue (B) color channels of the smartphone cameras, we exploit all three channels of RGB sensing to distill the SpO $_2$ information beyond the traditional ratio-of-ratios (RoR) method that uses only two wavelengths. To further facilitate an accurate SpO $_2$ prediction, we design adaptive narrow bandpass filters based on accurately estimated heart rate to obtain the most cardiac-related AC component for each color channel. Experimental results show that our proposed blood oxygen estimation method can reach a mean absolute error of 1.26% when a pulse oximeter is used as a reference, outperforming the traditional RoR method by 25%.

1 August 2021 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
LELauren E. Eagan
Lauren E. Eagan
CCCatalina A. Chesney
Catalina A. Chesney
SMSara E. Mascone
Sara E. Mascone
NSNinette Shenouda
Ninette Shenouda
SRSushant M. Ranadive
Sushant M. Ranadive
Endogenous sex hormone concentrations vary between healthy naturally menstruating (non-OCP) and oral contraceptive pill-using (OCP) women, as well as across cycles. The aim of this study was to investigate potential differences in concentrations of inflammatory cytokine interleukin-6 (IL-6) and vasoconstrictive substance endothelin-1 (ET-1) and measures of vascular function among relatively lower- and higher-hormone phases of non-OCP and OCP women. Concentrations of estrogen, progesterone, IL-6, and ET-1 and measures of vascular function were collected in 22 women (22 ± 1 yr, OCP: n = 12) during the early follicular (EF, ≤5 days of menstruation onset) and early luteal (EL, 4 ± 2 days postovulation) phases of non-OCP subjects and were compared to the placebo pill (PP, ≤5 days of PP onset) and active pill (AP, ≤5 days of highest-dose AP) phases of OCP subjects. Vascular function was assessed via brachial artery flow-mediated dilation (%FMD). Concentrations of endogenous estrogen and progesterone were higher in the EL phase compared with the EF phase of non-OCP (P = 0.01) but were similar between phases of OCP (P > 0.05). IL-6 was higher in non-OCP during the EF phase compared with the EL phase (P = 0.03) as well as compared with OCP during the PP phase (P = 0.002) but was similar between groups during the EL and AP phases, respectively (P > 0.05). Concentrations of ET-1 and measures of %FMD were similar between groups and unaffected by phase (P > 0.05). Thus, there exists variation in inflammation between young, healthy non-OCP and OCP women during the lower-hormone phase, despite similarities in vascular function and concentrations of ET-1 between groups and phases. NEW & NOTEWORTHY We demonstrate that despite having similar macrovascular function and concentrations of the vasoconstrictive substance endothelin-1 (ET-1) healthy naturally menstruating women display higher concentrations of circulating IL-6 during the lower-hormone phase of their menstrual cycle compared with 1) the higher-hormone phase of their menstrual cycle and 2) the lower-hormone phase of healthy women using oral contraceptive pills.

1 December 2021 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
MDMichele N. D’aGata
Michele N. D’aGata
EHElissa K. Hoopes
Elissa K. Hoopes
FBFelicia R. Berube
Felicia R. Berube
AHAlexandra E. Hirt
Alexandra E. Hirt
AKAndrew V. Kuczmarski
Andrew V. Kuczmarski
MWMelissa A. Witman
Melissa A. Witman
Black women (BLW) have a higher prevalence of cardiovascular disease (CVD) morbidity and mortality compared with White women (WHW). A racial disparity in CVD risk has been identified early in life as young adult BLW demonstrate attenuated vascular function compared with WHW. Previous studies comparing vascular function between premenopausal WHW and BLW have been limited to the early follicular (EF) phase of the menstrual cycle, which may not reflect their vascular function during other menstrual phases. Therefore, we evaluated peripheral microvascular function in premenopausal WHW and BLW using passive leg movement (PLM) during three menstrual phases: EF, ovulation (OV), and mid-luteal (ML). We hypothesized that microvascular function would be augmented during the OV and ML phases compared with the EF phase in both groups, but would be attenuated in BLW compared with WHW at all three phases. PLM was performed on 26 apparently healthy premenopausal women not using hormonal contraceptives: 15 WHW (23 ± 3 yr), 11 BLW (24 ± 5 yr). There was a main effect of race on the overall change in leg blood flow (ΔLBF) (P = 0.01) and leg blood flow area under the curve (LBF AUC) (P = 0.02), such that LBF was lower in BLW. However, there was no effect of phase on ΔLBF (P = 0.69) or LBF AUC (P = 0.65), nor an interaction between race and phase on ΔLBF (P = 0.37) or LBF AUC (P = 0.75). Despite peripheral microvascular function being unchanged across the menstrual cycle, a racial disparity was apparent as microvascular function was attenuated in BLW compared with WHW across the menstrual cycle. NEW & NOTEWORTHY This is the first study to compare peripheral microvascular function between young, otherwise healthy Black women and White women at multiple phases of the menstrual cycle. Our novel findings demonstrate a significant effect of race on peripheral microvascular function such that Black women exhibit significant attenuations in microvascular function across the menstrual cycle compared with White women.

1 August 2017 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
SRSushant M. Ranadive
Sushant M. Ranadive
AEAndy R. Eugene
Andy R. Eugene
GDGabrielle Dillon
Gabrielle Dillon
WNWayne T. Nicholson
Wayne T. Nicholson
MJMichael J. Joyner
Michael J. Joyner
The vasodilatory mechanism of Nntroglycerin (NTG) is similar to sodium nitroprusside (SNP) in regard to action on guanosine 3′5′-monophosphate (cyclic GMP) via nitric oxide. However, it is unknown whether NTG can achieve the same magnitude of vasodilation in the forearm as SNP. Therefore, the purpose of the study was to evaluate the differences in forearm blood flow (FBF) and forearm vascular conductance (FVC) during escalating infusions of NTG vs. SNP at similar concentration doses and rates. We measured FBF using venous occlusion plethysmography (VOP) and Doppler ultrasound in eight young, healthy participants (mean age = 28 ± 2 yr) during four forearm volume (FAV)-specific doses (0.25, 0.5, 1, and 2 µg·100 ml FAV−1·min−1) of SNP and NTG infused via a brachial artery catheter. There was a significant difference in FVC of SNP vs. NTG only at the higher doses, as measured by VOP (14.9 ± 1.4 and 18.3 ± 1.5 vs. 11.6 ± 1.2 and 12.5 ± 1.2 ml/dl FAV−1·min−1·100 mmHg−1). FVC as measured by Doppler ultrasound unadjusted for FAV was significantly different at the lowest and the higher two doses of SNP compared with NTG (202.1 ± 25.8, 329.4 ± 46.7, and 408 ± 63.5 vs. 142.9 ± 22.4, 217.2 ± 18.8, and 247.5 ± 18.2 ml·min−1·100 mmHg−1). SNP induces significantly higher vasodilatory actions compared with NTG. However, NTG is comparable in eliciting equivalent vasodilator effects to SNP during low concentration doses when measured by VOP. Importantly, for forearm pharmacology studies, NTG can elicit marked endothelium-independent forearm vasodilation. NEW & NOTEWORTHY We compared the vasodilatory capacities of NTG vs. SNP at similar concentration doses and rates into the forearm. Based on the results of the study, it may be feasible to use intra-arterial NTG as a measure of endothelial-independent vasodilator in research studies. However, NTG dosing may need to be higher if used as an endothelial-independent vasodilator due to significant differences in the vasodilatory effects during higher doses of SNP compared with NTG.

28 February 2021 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
EHElissa K. Hoopes
Elissa K. Hoopes
MDMichele N. D’AGata
Michele N. D’AGata
FBFelicia R. Berube
Felicia R. Berube
SRSushant M. Ranadive
Sushant M. Ranadive
FPFreda Patterson
Freda Patterson
MWMelissa A. Witman
Melissa A. Witman
Sleep irregularity is predictive of poor health outcomes, and particularly those of cardiometabolic origins. The immune system is implicated in the pathogenesis of cardiometabolic diseases, however the relation between sleep regularity and immune cell profile is unclear. Forty-two healthy young adults (20 ​± ​2 years) completed 14 days of 24-h wrist actigraphy followed by a morning blood sample to evaluate circulating white blood cells (WBC) and subtypes (neutrophils, lymphocytes, monocytes). Sleep regularity was operationalized as the standard deviation (SD) of nightly sleep duration and SD of sleep onset time. Every 60-min increase in sleep duration SD was associated with an estimated 2.7 ​± ​0.60 x103 ​cells/μL (p<0.001) increase in total WBC count, while every 60-min increase in sleep onset SD was associated with an estimated 2.4 ​± ​0.60 x103 ​cells/μL (p<0.001) increase in WBCs. Sleep duration SD was also associated with lymphocyte count (11.5 ​± ​3.8 ​cells/μL per 1-min increase, p<0.01), while sleep onset SD was associated with neutrophil (34.7 ​± ​9.8 ​cells/μL per 1-min increase, p<0.01) and monocyte counts (3.0 ​± ​0.9 ​cells/μL per 1-min increase, p<0.01). Sleep regularity metrics remained significantly associated with WBCs in a series of regressions which adjusted for sex, body mass index, resting blood pressure, mean sleep duration, physical activity, dietary sodium, and alcohol consumption. Unfavorable associations between irregular sleep patterns and circulating immune cells are apparent in young adulthood. These findings contribute to the growing body of evidence suggesting that consistent sleep schedules are an important dimension of sleep and circadian health and may reduce excess chronic disease risk.